Intravenous Ketamine for Treatment-Resistant Depression

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Depressive Disorder, Treatment-ResistantTreatment Resistant Depression (TRD)
Interventions
DRUG

Ketamine

The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment

DRUG

Normal Saline

The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Mayo Clinic

OTHER

NCT06668571 - Intravenous Ketamine for Treatment-Resistant Depression | Biotech Hunter | Biotech Hunter